Gilead Sciences

Gilead to Buy Cancer Drugmaker for $21 Billion
M&A

Gilead to Buy Cancer Drugmaker for $21 Billion

The acquisition of Immunomedics "represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio."
By Matthew Heller | September 14, 2020
Read More
Gilead Works to ‘Maximize Global Supply’ Of Coronavirus Candidate Remdesivir
Supply Chain

Gilead Works to ‘Maximize Global Supply’ Of Coronavirus Candidate Remdesivir

"Close coordination of remdesivir manufacturing will be critical," said Gilead Sciences.
By Vincent Ryan | May 6, 2020
Read More
Gilead to Buy Forty Seven for $4.9B
M&A

Gilead to Buy Forty Seven for $4.9B

The deal adds to Gilead's presence in immuno-oncology, an approach to treating cancer that harnesses the body's immune system.
By Lauren Muskett | March 2, 2020
Read More
CFOs on the Move: Week Ending May 3
People

CFOs on the Move: Week Ending May 3

Home Depot, Gilead Sciences, Argonne National Lab, Globe Photos, American Water, Talos Energy, Ryan Cos., Insurance Auto Actions, VIQ Solutions, Trinseo
By Joan Urdang | May 3, 2019
Read More
Gilead Flies Into Cancer Therapy With Kite Deal
Strategy

Gilead Flies Into Cancer Therapy With Kite Deal

The $11.9 billion acquisition gives Gilead access to the oncology market as its hepatitis C drugs face declining sales.
By Matthew Heller | August 28, 2017
Read More
Corporate Bond Market Booming
Investment Banking

Corporate Bond Market Booming

The flurry of deals came after issuance virtually halted for nearly two weeks.
By Katie Kuehner-Hebert | September 10, 2015
Read More
Quick Take: Gilead Sciences CFO Robin Washington
Profiles

Quick Take: Gilead Sciences CFO Robin Washington

A biotech finance chief shares her thoughts on the CFO role.
By Kate O'Sullivan | July 25, 2012
Read More